BeyondSpring vs Crescent Biopharma
BYSI and CBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BYSI and CBIO compare
Crescent Biopharma scores higher on the StockData Score (7 against 4 for BeyondSpring), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BYSI | CBIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $548M |
| Share price | $0.644 | $14.76 |
| Change, 1 year | −66.6% | 12.5% |
| Change, 5 years | −95.1% | −92.2% |
| Beta (5Y) | 0.54 | 1.63 |
| Employees | 44 | 44 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 3.4× |
| FCF yield | – | −13.4% |
| Growth | ||
| Revenue growth, 5Y average | – | 1.3% |
| Profitability | ||
| Return on equity | – | −63.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.70 | 9.66 (better) |
| Altman Z-score | – | 13.19 |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 14.7% | 79.7% |
| Held by insiders | 31.2% | 38.6% |
| Insider net buying, 12 months | $0 | $29.1M (better) |
| Short interest, % of float | 8.0% | 18.3% |
Go deeper
- BYSI stock overview
- BYSI income statement
- BYSI valuation and score
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.